1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Obesity - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2019-2024) and Forecast (2025-2035)
4.4 Market Overview (2019-2024) and Forecast (2025-2035)
4.5 Competitive Intelligence
5 Obesity - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 Patient Journey
7 Obesity - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2019-2024)
7.2.2 Epidemiology Forecast (2025-2035)
7.2.3 Epidemiology by Age (2019-2035)
7.2.4 Epidemiology by Gender (2019-2035)
7.2.5 Epidemiology by Type (2019-2035)
7.2.6 Diagnosed Cases (2019-2035)
7.2.7 Patient Pool/Treated Cases (2019-2035)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2019-2024)
7.3.2 Epidemiology Forecast (2025-2035)
7.3.3 Epidemiology by Age (2019-2035)
7.3.4 Epidemiology by Gender (2019-2035)
7.3.5 Epidemiology by Type (2019-2035)
7.3.6 Diagnosed Cases (2019-2035)
7.3.7 Patient Pool/Treated Cases (2019-2035)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2019-2024)
7.4.2 Epidemiology Forecast (2025-2035)
7.4.3 Epidemiology by Age (2019-2035)
7.4.4 Epidemiology by Gender (2019-2035)
7.4.5 Epidemiology by Type (2019-2035)
7.4.6 Diagnosed Cases (2019-2035)
7.4.7 Patient Pool/Treated Cases (2019-2035)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2019-2024)
7.5.2 Epidemiology Forecast (2025-2035)
7.5.3 Epidemiology by Age (2019-2035)
7.5.4 Epidemiology by Gender (2019-2035)
7.5.5 Epidemiology by Type (2019-2035)
7.5.6 Diagnosed Cases (2019-2035)
7.5.7 Patient Pool/Treated Cases (2019-2035)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2019-2024)
7.6.2 Epidemiology Forecast (2025-2035)
7.6.3 Epidemiology by Age (2019-2035)
7.6.4 Epidemiology by Gender (2019-2035)
7.6.5 Epidemiology by Type (2019-2035)
7.6.6 Diagnosed Cases (2019-2035)
7.6.7 Patient Pool/Treated Cases (2019-2035)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2019-2024)
7.7.2 Epidemiology Forecast (2025-2035)
7.7.3 Epidemiology by Age (2019-2035)
7.7.4 Epidemiology by Gender (2019-2035)
7.7.5 Epidemiology by Type (2019-2035)
7.7.6 Diagnosed Cases (2019-2035)
7.7.7 Patient Pool/Treated Cases (2019-2035)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2019-2024)
7.8.2 Epidemiology Forecast (2025-2035)
7.8.3 Epidemiology by Age (2019-2035)
7.8.4 Epidemiology by Gender (2019-2035)
7.8.5 Epidemiology by Type (2019-2035)
7.8.6 Diagnosed Cases (2019-2035)
7.8.7 Patient Pool/Treated Cases (2019-2035)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2019-2024)
7.9.2 Epidemiology Forecast (2025-2035)
7.9.3 Epidemiology by Age (2019-2035)
7.9.4 Epidemiology by Gender (2019-2035)
7.9.5 Epidemiology by Type (2019-2035)
7.9.6 Diagnosed Cases (2019-2035)
7.9.7 Patient Pool/Treated Cases (2019-2035)
8 Obesity Treatment - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 Obesity Treatment - Unmet Needs
10 Obesity Treatment - Key Endpoints of Treatment
11 Obesity Treatment - Marketed Products
11.1 List of Obesity Treatment - Marketed Drugs Across the Top 7 Markets
11.1.1 Xenical (Orlistat) - Roche
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Clinical Trial Results
11.1.1.4 Safety and Efficacy
11.1.1.5 Regulatory Status
11.1.2 Qsymia (Phentermine/topiramate) - VIVUS
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Clinical Trial Results
11.1.2.4 Safety and Efficacy
11.1.2.5 Regulatory Status
11.1.3 Contrave (Bupropion/naltrexone) - Currax Pharma
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Clinical Trial Results
11.1.3.4 Safety and Efficacy
11.1.3.5 Regulatory Status
11.1.4 Saxenda (Liraglutide) - Novo Nordisk
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Clinical Trial Results
11.1.4.4 Safety and Efficacy
11.1.4.5 Regulatory Status
11.1.5 Wegovy (Semaglutide) - Novo Nordisk
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Clinical Trial Results
11.1.5.4 Safety and Efficacy
11.1.5.5 Regulatory Status
Complete list to be provided in the final report.
12 Obesity Treatment - Pipeline Products
12.1 List of Obesity Treatment Pipeline Drugs Across the Top 7 Markets
12.1.1 Maridebart cafraglutide (AMG 133) - Amgen
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Orforglipron (LY3502970) - Eli Lilly and Company
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Survodutide - Boehringer Ingelheim
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 CT 388 - Carmot Therapeutics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 LY3437943 (Retatrutide) - Eli Lilly and Company
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Complete list to be provided in the final report.
13 Obesity Treatment - Attribute Analysis of Key Marketed and Pipeline Drugs
14 Obesity Treatment – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 Obesity Treatment Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Obesity Treatment - Market Size
15.2.1.1 Market Size (2019-2024)
15.2.1.2 Market Forecast (2025-2035)
15.2.2 Obesity Treatment - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2019-2024)
15.2.2.2 Market Forecast by Therapies (2025-2035)
15.3 Market Scenario - United States
15.3.1 Obesity Treatment - Market Size
15.3.1.1 Market Size (2019-2024)
15.3.1.2 Market Forecast (2025-2035)
15.3.2 Obesity Treatment- Market Size by Therapies
15.3.2.1 Market Size by Therapies (2019-2024)
15.3.2.2 Market Forecast by Therapies (2025-2035)
15.3.3 Obesity Treatment- Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Obesity Treatment - Market Size
15.4.1.1 Market Size (2019-2024)
15.4.1.2 Market Forecast (2025-2035)
15.4.2 Obesity Treatment- Market Size by Therapies
15.4.2.1 Market Size by Therapies (2019-2024)
15.4.2.2 Market Forecast by Therapies (2025-2035)
15.4.3 Obesity Treatment- Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Obesity Treatment - Market Size
15.5.1.1 Market Size (2019-2024)
15.5.1.2 Market Forecast (2025-2035)
15.5.2 Obesity Treatment- Market Size by Therapies
15.5.2.1 Market Size by Therapies (2019-2024)
15.5.2.2 Market Forecast by Therapies (2025-2035)
15.5.3 Obesity Treatment- Access and Reimbursement Overview
15.6 Market Scenario – United Kingdom
15.6.1 Obesity Treatment - Market Size
15.6.1.1 Market Size (2019-2024)
15.6.1.2 Market Forecast (2025-2035)
15.6.2 Obesity Treatment- Market Size by Therapies
15.6.2.1 Market Size by Therapies (2019-2024)
15.6.2.2 Market Forecast by Therapies (2025-2035)
15.6.3 Obesity Treatment- Access and Reimbursement Overview
15.7 Market Scenario – Italy
15.7.1 Obesity Treatment - Market Size
15.7.1.1 Market Size (2019-2024)
15.7.1.2 Market Forecast (2025-2035)
15.7.2 Obesity Treatment- Market Size by Therapies
15.7.2.1 Market Size by Therapies (2019-2024)
15.7.2.2 Market Forecast by Therapies (2025-2035)
15.7.3 Obesity Treatment- Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Obesity Treatment - Market Size
15.8.1.1 Market Size (2019-2024)
15.8.1.2 Market Forecast (2025-2035)
15.8.2 Obesity Treatment- Market Size by Therapies
15.8.2.1 Market Size by Therapies (2019-2024)
15.8.2.2 Market Forecast by Therapies (2025-2035)
15.8.3 Obesity Treatment- Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Obesity Treatment - Market Size
15.9.1.1 Market Size (2019-2024)
15.9.1.2 Market Forecast (2025-2035)
15.9.2 Obesity Treatment- Market Size by Therapies
15.9.2.1 Market Size by Therapies (2019-2024)
15.9.2.2 Market Forecast by Therapies (2025-2035)
15.9.3 Obesity Treatment - Access and Reimbursement Overview
16 Obesity Treatment - Recent Events and Inputs From Key Opinion Leaders
17 Obesity Treatment Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 Obesity – Strategic Recommendations
19 Appendix